Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer|Metastatic Breast Cancer|Breast Cancer|Breast Carcinoma|Cancer of the Breast|Cancer of Breast|Malignant Tumor of Breast|Breast Tumor
Interventions: DRUG: NUV-422|DRUG: Fulvestrant
Sponsor: Nuvation Bio Inc.